WCLC 2023 | How can treatment outcomes in limited-stage SCLC be improved?

Bjørn Henning Grønberg, MD PhD, Norwegian University of Science and Technology, Trondheim, Norway, shares the challenges in treating limited and extensive stage non-small cell lung cancer (NSCLC). In both types of NSCLC, choosing effective treatments is difficult due to the lack of predictive and prognostic factors and an unrefined classification system. Potential strategies to combat these challenges include circulating tumor (ct-DNA) analysis before and after primary therapy in order to evaluate the treatment response. Dr Grønberg comments on the importance of comparing ct-DNA data with 18F-FDG PET/CT imaging as the latter is a strong prognostic factor. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.